Enveric Biosciences (ENVB) Competitors $1.25 +0.01 (+0.40%) As of 07/3/2025 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENVB vs. NERV, EYEN, ALVR, ATHA, IBIO, EQ, CTXR, BGXX, PHIO, and BCDAShould you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Minerva Neurosciences (NERV), Eyenovia (EYEN), AlloVir (ALVR), Athira Pharma (ATHA), iBio (IBIO), Equillium (EQ), Citius Pharmaceuticals (CTXR), Bright Green (BGXX), Phio Pharmaceuticals (PHIO), and BioCardia (BCDA). These companies are all part of the "pharmaceutical products" industry. Enveric Biosciences vs. Its Competitors Minerva Neurosciences Eyenovia AlloVir Athira Pharma iBio Equillium Citius Pharmaceuticals Bright Green Phio Pharmaceuticals BioCardia Enveric Biosciences (NASDAQ:ENVB) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Does the media prefer ENVB or NERV? In the previous week, Enveric Biosciences' average media sentiment score of 0.00 equaled Minerva Neurosciences'average media sentiment score. Company Overall Sentiment Enveric Biosciences Neutral Minerva Neurosciences Neutral Is ENVB or NERV more profitable? Minerva Neurosciences' return on equity of -20.68% beat Enveric Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Enveric BiosciencesN/A -250.28% -195.57% Minerva Neurosciences N/A -20.68%15.73% Do analysts prefer ENVB or NERV? Enveric Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 696.81%. Minerva Neurosciences has a consensus target price of $5.00, indicating a potential upside of 194.12%. Given Enveric Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Enveric Biosciences is more favorable than Minerva Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, ENVB or NERV? Enveric Biosciences has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500. Do institutionals and insiders believe in ENVB or NERV? 13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 1.1% of Enveric Biosciences shares are owned by company insiders. Comparatively, 8.6% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, ENVB or NERV? Enveric Biosciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnveric BiosciencesN/AN/A-$9.57M-$38.38-0.03Minerva NeurosciencesN/AN/A$1.44M$0.822.07 SummaryMinerva Neurosciences beats Enveric Biosciences on 7 of the 11 factors compared between the two stocks. Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENVB vs. The Competition Export to ExcelMetricEnveric BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.10M$2.88B$5.50B$9.01BDividend YieldN/A2.43%5.38%4.04%P/E Ratio-0.0321.5627.6020.30Price / SalesN/A172.94369.09103.84Price / CashN/A41.9536.6357.47Price / Book0.537.518.055.68Net Income-$9.57M-$55.05M$3.18B$249.13M7 Day Performance1.21%4.61%2.82%3.30%1 Month Performance-2.71%4.89%3.70%5.20%1 Year Performance-83.84%5.84%35.41%21.38% Enveric Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENVBEnveric Biosciences2.645 of 5 stars$1.26+0.4%$10.00+696.8%-83.8%$3.10MN/A-0.0320NERVMinerva Neurosciences3.2061 of 5 stars$1.77flat$5.00+182.5%-45.9%$12.38MN/A2.169Gap DownEYENEyenovia1.0686 of 5 stars$5.48+30.2%$2.00-63.5%-74.0%$12.14M$60K-0.0940High Trading VolumeALVRAlloVirN/A$2.40-6.6%N/A-84.9%$12.10MN/A-0.12110Gap UpHigh Trading VolumeATHAAthira Pharma2.7668 of 5 stars$0.30-2.3%$11.25+3,700.7%-87.1%$11.83MN/A-0.1440Gap DownIBIOiBio1.7193 of 5 stars$0.71-7.6%$4.30+503.6%-63.0%$11.77M$375K0.00100High Trading VolumeEQEquillium1.8642 of 5 stars$0.29-11.3%$3.00+934.5%-50.6%$11.68M$41.10M-0.7440Gap UpCTXRCitius Pharmaceuticals2.1895 of 5 stars$1.03-4.6%$54.50+5,191.3%-81.9%$11.48MN/A0.0020High Trading VolumeBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownPHIOPhio Pharmaceuticals2.8184 of 5 stars$2.18-4.0%$14.00+542.2%-53.4%$10.87MN/A-0.2010BCDABioCardia4.0006 of 5 stars$2.02-2.9%$25.00+1,137.6%-29.4%$10.77M$3K-0.8740News CoveragePositive NewsInsider TradeGap Up Related Companies and Tools Related Companies NERV Alternatives EYEN Alternatives ALVR Alternatives ATHA Alternatives IBIO Alternatives EQ Alternatives CTXR Alternatives BGXX Alternatives PHIO Alternatives BCDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENVB) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENVB Stock Alerts